A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

NCT06499350 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumors

Interventions

DRUG: FC084CSA+Tislelizumab combination (dose escalation)
DRUG: RP2D of FC084CSA+Tislelizumab combination (dose expansion)

Sponsor

FindCure Biosciences (ZhongShan) Co., Ltd.